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Summary
 
A growing number of human tumor antigens have been described that can be recognized by
cytotoxic T lymphocytes (CTLs) in a major histocompatibility complex (MHC) class I–restricted
fashion. Serological screening of cDNA expression libraries, SEREX, has recently been shown
to provide another route for defining immunogenic human tumor antigens. The detection of
antibody responses against known CTL-defined tumor antigens, e.g., MAGE-1 and tyrosinase,
raised the question whether antibody and CTL responses against a defined tumor antigen can
occur simultaneously in a single patient. In this paper, we report on a melanoma patient with a
high-titer antibody response against the “cancer–testis” antigen NY-ESO-1. Concurrently, a
strong MHC class I–restricted CTL reactivity against the autologous NY-ESO-1–positive tu-
mor cell line was found. A stable CTL line (NW38-IVS-1) was established from this patient
that reacted with autologous melanoma cells and with allogeneic human histocompatibility
leukocyte antigen (HLA)-A2
 
2
 
, NY-ESO-1–positive, but not NY-ESO-1–negative, melanoma
cells. Screening of NY-ESO-1 transfectants with NW38-IVS-1 revealed NY-ESO-1 as the
relevant CTL target presented by HLA-A2. Computer calculation identified 26 peptides with
HLA-A2–binding motifs encoded by NY-ESO-1. Of these, three peptides were efficiently
recognized by NW38-IVS-1. Thus, we show that antigen-specific humoral and cellular im-
mune responses against human tumor antigens may occur simultaneously. In addition, our
analysis provides a general strategy for identifying the CTL-recognizing peptides of tumor anti-
gens initially defined by autologous antibody.
 
T
 
here is growing evidence for humoral and cellular im-
mune recognition of cancer by the autologous human
host (1–6). Based on CTL-dependent lysis of cultured mel-
anoma cell lines, several categories of autoimmunogenic
tumor antigens have been characterized, including differ-
entiation antigens of specific cell lineages (7–9), individual
antigens caused by point mutations (10, 11), and tumor an-
tigens, such as MAGE, which are expressed in a variable
proportion of different tumor types, but are silent in most
normal tissues except the testis (12). CTL responses against
melanoma antigens induced by peptide vaccines in vivo
have been associated with a favorable development of ad-
vanced melanoma in some patients (6, 13). As immunose-
lection of antigen-negative tumor cell variants has been
observed during peptide vaccination (14), the molecular
characterization of additional CTL-defined tumor antigens
is needed to develop polyvalent vaccines with broader im-
munotherapeutic effects.
Sahin et al. have recently introduced a powerful new
methodology for identifying human tumor antigens elicit-
ing humoral immune response (5). The method has been
called SEREX, for serological expression cloning of recom-
binant cDNA libraries of human tumors. Novel and previ-
ously defined tumor antigens have been identified by the
SEREX method, including MAGE-1 and tyrosinase, both
originally identified by cloning the epitopes recognized by
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CTLs. Thus, antibody screening of cDNA libraries pre-
pared from human tumors can be used to identify antigens
eliciting a cellular immune response, including CTLs, cir-
cumventing the need for established cultured autologous
cell lines and stable CTL lines.
We have recently identified a novel human tumor anti-
gen by SEREX analysis of a human esophageal cancer (15).
The antigen, NY-ESO-1, belongs to a growing number of
human tumor antigens we have called “cancer–testis” anti-
gens that include MAGE, GAGE, BAGE (1), and SSX2
(HOM-MEL-40) (5, 16). These antigens have the follow-
ing characteristics: (
 
a
 
) they are expressed in a variable por-
tion of a wide range of cancers, (
 
b
 
) their normal tissue ex-
pression is generally restricted to the testis, and (
 
c
 
) they are
generally coded for by genes on the X chromosome. In a re-
cent survey of sera from normal individuals and cancer pa-
tients, antibodies against NY-ESO-1 were found in 
 
z
 
10%
of patients with melanoma, ovarian cancer, and other can-
cers, but not in normal individuals (Stockert, E., manuscript in
preparation). One patient with a high NY-ESO-1 antibody
response was found to have specific CTL reactivity against
cultured autologous melanoma cells. In the present study, we
report that NY-ESO-1 encodes the CTL target in this pa-
tient and identify the NY-ESO-1 peptides that are recognized.
 
Materials and Methods
 
Patient.
 
The 81-yr-old female patient NW38 was diagnosed
with malignant melanoma involving her right thigh in 1993. Af-
ter resection of the primary tumor, she developed metastatic dis-
ease in inguinal, parailiacal, and paraaortic lymph nodes. Disease
progression was observed in the right inguinal region, leading to a
necrotising tumor metastases of 
 
.
 
9 cm in diameter. A transcuta-
neous needle biopsy was obtained from this area in 1995 to con-
firm the diagnosis of melanoma and to establish the tumor cell
line NW-MEL-38. The patient typed HLA-A1 and -A2 positive.
PBLs were collected, and a 6-wk course of chemotherapy with
vindesin was given. Serum was collected repeatedly before and
during chemotherapy. The patient died of tumor progression 26
wk after the start of chemotherapy, without evidence of brain
metastasis.
 
Cell Cultures.
 
Melanoma cell line NW-MEL-38 was estab-
lished in our laboratory (Krankenhaus Nordwest, Frankfurt, Ger-
many) from a lymph node metastasis of patient NW38. Cell lines
designated MZ have been established in our former laboratory
(Johannes Gutenberg Universität, Mainz, Germany) and cell lines
designated SK were from the tumor cell bank at the Ludwig In-
stitute for Cancer Research, (New York). Cells were cultured in
DME (GIBCO, BRL, Gaithersburg, MD) containing 10 mM Hepes
buffer, 
 
l
 
-arginine (84 mg/liter), 
 
l
 
-glutamine (584 mg/liter), pen-
icillin (10 IU/ml), streptomycin (100 
 
m
 
g/ml), and 10% FCS.
EBV-transformed B lymphocytes, MZ1257-EBV, used as feeder
cells in the mixed lymphocyte tumor cell culture, and the mutant
cell line CEM 
 
3
 
 721.174.T2 (T2) were maintained in RPMI
1640 medium supplemented with 10 mM Hepes, 
 
l
 
-arginine (242
mg/liter), 
 
l
 
-asparagine (50 mg/liter), 
 
l
 
-glutamine (300 mg/liter),
penicillin (10 IU/ml), streptomycin (100 
 
m
 
g/ml), 1% non-essen-
tial amino acids, and 10% FCS.
Mixed lymphocyte tumor cell cultures of PBLs and the autolo-
gous tumor cell line from patient NW38 were performed as pre-
viously described (17). The stable CTL line NW38-IVS-1 was
maintained by weekly restimulation of 2–3 
 
3
 
 10
 
5
 
 CTLs with 5 
 
3
 
10
 
4
 
 autologous melanoma cells and 2 
 
3
 
 10
 
5
 
 MZ1257-EBV cells
as feeders.
 
Reverse Transcriptase PCR Analysis of NY-ESO-1 Expression.
 
Total RNA was isolated from tumor samples frozen in liquid ni-
trogen and from melanoma cell lines using the RNeasy kit
(Qiagen, Chatsworth, CA), according to the instructions of the
manufacturer. 2 
 
m
 
g of each sample were subjected to cDNA
synthesis using the Ready-To-Go first strand synthesis kit (Phar-
macia Biotech, Piscataway, NJ). PCR was subsequently per-
formed to analyze the expression of NY-ESO-1. Primers were:
ESO1A, 5
 
9
 
-CACACAGGATCCATGGATGCTGCAGATG-
CGG-3
 
9
 
; and ESO1B, 5
 
9
 
-CACACAAAGCTTGGCTTAG-
CGCCTCTGCCCTG-3
 
9
 
 (Operon Technologies, Alameda). Am-
plification was performed using 35 cycles at an annealing temperature
of 60
 
8
 
C. PCR products were visualized by ethidium bromide
staining after separation over a 1.5% agarose gel.
 
Prokaryotic Expression Cloning of NY-ESO-1.
 
To produce full-
length NY-ESO-1 recombinant protein, the coding sequence for
the protein was PCR amplified from a corresponding cDNA
clone in pBK-CMV phagemid, and cloned into pQE9, a plasmid
vector containing histidine tags (Qiagen). PCR primers for
NY-ESO-1 amplification were ESO1A(FL), 5
 
9
 
-CACACAGGA-
TCCATGCAGGCCGAAGGCCGG-3
 
9
 
; and ESO1B (described
above). After transformation into 
 
Escherichia coli
 
 strain XL1-Blue,
positive transformants were confirmed to contain the appropriate
insert by restriction mapping and DNA sequencing. Recombinant
NY-ESO-1 protein was then produced by isopropyl 
 
b
 
-
 
d
 
-thioga-
lactoside (IPTG) induction and purified by Ni
 
2
 
1
 
 affinity chroma-
tography, following procedures recommended by the manufac-
turer (Qiagen). Concentration of the purified protein was determined
by colorimetric protein quantification assay (BioRad Labs., Her-
cules, CA).
 
Immunoblot Analysis.
 
Serum antibody responses against the
full-length recombinant NY-ESO-1 protein, a lysate of NY-
ESO-1–transfected COS-7 cells, and a lysate of the autologous
tumor cell line NW-MEL-38 were tested by standard Western
blot analysis (18). In brief, 1 
 
m
 
g of NY-ESO-1 protein or lysates
of 2 
 
3
 
 10
 
4
 
 NY-ESO-1–transfected COS-7 cells (containing 7.7 
 
m
 
g
of protein) or of 5 
 
3
 
 10
 
3
 
 tumor cells were diluted in SDS, and
electrophoresed on a 15% SDS gel. After overnight blotting on a
nitrocellulose filter (0.45 
 
m
 
m; Sartorius, Göttingen, Germany)
and blocking with 3% BSA, blots were incubated with serum of
patient NW38 at 1:1,000, 1:10,000, and 1:100,000 dilution, or
with a mouse monoclonal antibody against NY-ESO-1 (Stockert,
E., manuscript in preparation) as a positive control. Serum antibod-
ies binding to NY-ESO-1 were detected by incubation with goat
anti–human IgG (Fc-specific; Sigma Chemical Co., St. Louis,
MO) at a ratio of 1:10,000, and visualized with NBT/X-phos-
phate (Sigma Chemical Co.).
 
Prediction of HLA-A2–binding Peptides Encoded by NY-ESO-1
and Peptide Synthesis.
 
NY-ESO-1 peptides with HLA-A2–bind-
ing motifs were predicted by computer analysis as described (19).
Peptides were synthesized using a multiple peptide synthesizer
(Abimed 422; Abimed, Langenfeld, Germany). Peptides were iso-
lated and purified by repeated ether precipitations. The purity
was determined by analytical reversed phase HPLC and proved to
be at least 80% pure. Integrity of the peptides was determined by
laser desorption time-of-flight mass spectrometry on a Lasermat
mass spectrometer (Finnigan MAT, UK).
 
Cytotoxicity Assays.
 
Lytic activity of CTLs was tested in a 4-h
chromium release assay as previously described (3). Peptide-spe- 
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cific CTL reactivity was determined on T2 cells labeled with 100
 
m
 
Ci of Na(
 
51
 
Cr)O
 
4
 
, 10 
 
m
 
g/ml of peptide, and 2.5 
 
m
 
g/ml of 
 
b
 
2-
microglobulin. CTLs were added to the peptide-pulsed targets at
effector/target ratios of 90:1, 30:1, 10:1, and 1:1 for 4 h in V-bot-
tomed microwells. Radioactivity was measured in supernatants
(100 
 
m
 
l) in a gamma counter.
 
Eukaryotic Expression Cloning of NY-ESO-1.
 
For transfectional
studies, the full-length NY-ESO-1 sequence was isolated from
the corresponding pQE9 clone by restriction enzyme digestion,
and cloned into BamHI–HindIII sites of the pcDNA3.1(
 
2
 
) vec-
tor (Invitrogen, Carlsbad, CA). Transfection of COS-7 cells was
carried out as described (20). In brief, 2 
 
3
 
 10
 
4
 
 COS-7 cells were
transfected with 150 ng of plasmid pcDNA3.1(
 
2
 
) containing
NY-ESO-1 cDNA, and 150 ng of plasmid pcDNA1Amp con-
taining HLA-A2.1 or HLA-A1 cDNA using the DEAE-dextran-
chloroquine method. The transfectants were incubated at 37
 
8
 
C
for 48 h, and tested in a CTLs stimulation assay after 24 h.
 
Immunoscreening of NY-ESO-1 Transfectants.
 
Transfectants were
tested for their ability to stimulate the production of TNF-
 
a
 
 by
NW38-IVS-1, as described (20). In brief, 2,500 CTLs in 100 
 
m
 
l
RPMI supplemented with 10% human serum and 25 U/ml re-
combinant human IL-2 were added to microwells containing
COS-7 transfectants. After 24 h, the content of TNF-
 
a
 
/50 
 
m
 
l of
supernatant was determined by testing the cytotoxicity against
WEHI 164 clone 13 cells in a 3-(4,5dimethylthiazol-2-yl)-
2,5diphenyltetrazolium bromide (MTT) colorimetric assay.
 
Results
 
High-titer Antibody Reactivity against NY-ESO-1.
 
Mel-
anoma patient NW38 presented with extensive metastases
to inguinal lymph nodes having large areas of necrosis. Re-
verse transcriptase PCR of tumor RNA showed that this
tumor expressed NY-ESO-1. Based on the hypothesis that
exposure of the immune system to large amounts of intra-
cellular tumor proteins released from the necrotic tumor
might elicit a strong humoral immune response, the serum
of patient NW38 was tested for specific reactivity against
recombinant NY-ESO-1 protein. Fig. 1 shows the reactiv-
ity of NW38 serum with the recombinant NY-ESO-1 pro-
tein, with a lysate of NY-ESO-1–transfected COS-7 cells,
and with a lysate of the autologous NY-ESO-1 messenger
RNA–positive tumor cell line NW-MEL-38. A 22-kD
protein species was identified in both cell lysates, and comi-
grated with the purified recombinant NY-ESO-1 protein.
The identity of this protein species as NY-ESO-1 was fur-
ther confirmed by using an anti–NY-ESO-1 mouse mono-
clonal antibody. Reactivity against recombinant NY-ESO-1
protein was still detectable at a serum dilution of 1:100,000.
No reactivity was detected against a lysate of untransfected
COS-7 cells.
 
CTL Reactivity against Autologous and Allogeneic ESO-1
 
1
 
Tumor Cell Lines.
 
A tumor cell line was established from
tumor tissue obtained from an inguinal lymph node me-
tastasis by needle biopsy. Stimulation of autologous PBLs
by the tumor cell line, NW38-MEL-38 resulted in signifi-
cant lysis of the tumor cell targets, and a stable CTL cell
line, designated NW38-IVS-1, maintaining this reactivity was
established. The natural killer cell target K562 and autolo-
gous PHA blasts NW38-PHA were not lysed by NW38-
IVS-1. The observation of high-titer seroreactivity against
NY-ESO-1 indicated recognition of NY-ESO-1 by helper
T cells and suggested NY-ESO-1 as a possible antigenic
target for NW38-IVS-1. To evaluate this, several NY-
ESO-1 messenger RNA-positive and -negative allogeneic
melanoma lines were tested (Fig. 2). The allogeneic HLA-
A2
 
1
 
, NY-ESO-1
 
1
 
 melanoma cell lines SK-MEL-37 and
MZ-MEL-19 were lysed by NW38-IVS-1. The NY-
ESO-1
 
1
 
 melanoma cell line SK-MEL-19 lacking MHC
class I expression was not lysed, nor was the HLA-A2
 
1
 
,
NY-ESO-1
 
2
 
 melanoma cell line NW-MEL-145.
 
HLA-A2–restricted CTL Reactivity against NY-ESO-1
Transfectants.
 
The correlation between NY-ESO-1 ex-
pression and NW38-IVS-1 reactivity suggested NY-ESO-1
as the antigenic target. To prove this, COS-7 cells were
transfected with NY-ESO-1 cDNA and different MHC
class I molecules and used as targets for NW38-IVS-1. Re-
Figure 1. Western blot analy-
sis of NW38 serum antibody re-
activity. Lanes 1–5 contained 1
mg of recombinant NY-ESO-1
protein, tested against serum
from a healthy donor (lane 1),
NW38 serum (lanes 2–4, serum
dilutions 1:1,000, 1:10,000, and
1:100,000), or an anti–NY-ESO-1
mouse monoclonal antibody (lane
5, hybridoma supernatant 1:50
dilution). NW38 serum was also
tested, at 1:1,000 dilution, against
lysates of 5 3 103 autologous
NW-MEL-38 tumor cells (lane
6), of 2 3 104 untransfected COS-7 cells (lane 7), and of 2 3 104
NY-ESO-1–transfected COS-7 cells (lane 8).
Figure 2. Cytotoxicity of NW38-IVS-1 against NY-ESO-11 and NY-
ESO-12 cell lines. Specific lysis of the autologous NY-ESO-11 mela-
noma cell line NW-MEL-38, and the NY-ESO-11/HLA-A21 allogeneic
melanoma cell lines SK-MEL-37 and MZ-MEL-19 was observed. The
NY-ESO-11 MHC class I- melanoma cell line SK-MEL-19, the NY-
ESO-12 HLA-A21 melanoma cell line NW-MEL-145, K562, and
NW38 PHA blasts used as controls were not lysed. Values represent the
specific lysis of 51Cr-labeled target cells (E/T ratios: 90 [solid], 30 [check-
ered], 10 [striped], and 1:1 [open], as assessed by a standard 51Cr-release assay.268 Definition of HLA-2–binding Peptide Epitopes
activity was measured in a standard TNF-a release assay.
TNF release was found after stimulation of NW38-IVS-1
with COS-7 cells cotransfected with HLA-A22 and NY-
ESO-1 cDNA. No reactivity was detected after stimulation
with cotransfectants of pcDNA3.1(2)-NY-ESO-12 and
pcDNA1Amp-HLA-A1 cDNA, COS-7 cells transfected
with pcDNA3.1(2), or untransfected COS-7 cells (Fig. 3).
Peptide-specific CTLs. 26 different peptides encoded by
NY-ESO-1 with theoretical binding motifs to the HLA-
A2.1 molecule were tested for specific recognition by
NW38-IVS-1. The target cells were peptide-pulsed T2 cells.
Of these 26 peptides, three were recognized by NW38-
IVS-1 as determined by a standard 51Cr–release assay (Table
1). The peptide sequences SLLMWITQCFL, SLLM-
WITQC, and QLSLLMWIT are located between positions
155 and 167 of the NY-ESO-1 protein (15), and show
overlapping sequences. The 11-mer SLLMWITQCFL (2
in Table 1) and the 9-mer SLLMWITQC (12 in Table 1)
consist of identical amino acids at positions 1–9.
To provide additional confirmation of the peptide speci-
ficity, the 26 synthetic peptides were individually incubated
with HLA-A2–transfected COS-7 cells and tested in the TNF
release assay. Consistent with the results of 51Cr–release as-
say, specific TNF-a release was detected in tests with pep-
tides SLLMWITQCFL, SLLMWITQC, and QLSLLMWIT.
NY-ESO-1/HLA-A2 transfectants were used as a positive
control in these assays (Fig. 4).
Discussion
The search for tumor antigens that induce specific im-
mune responses in cancer patients is the ongoing challenge
in tumor immunology. Evidence for a specific humoral re-
sponse to human cancer came from serological analysis of
cell surface reactivity of sera from cancer patients for autol-
ogous cancer cells, an approach called autologous typing
(4). However, with only a few exceptions, this approach
did not allow for the structural definition of the antigenic
target. An autologous typing system also provided the first
Figure 3. TNF-a–release assays after stimulation of the CTL line
NW38-IVS-1 by COS-7 cell transfectants. TNF release was detected
against COS-7 cells cotransfected with the expression vector pcDNA3.1
(2) containing NY-ESO-1 cDNA, and pcDNA1Amp containing HLA-A2
cDNA. No TNF release was detected against COS-7 transfected with
vector alone, vector/HLA-A1, vector/HLA-A2, vector/NY-ESO-1, and
vector/NY-ESO-1/HLA-A1.
Figure 4. TNF-a–release assays after stimulation of CTL line NW38-
IVS-1 by HLA-A2–transfected COS-7 cells pulsed with HLA-A2–bind-
ing peptides encoded by NY-ESO-1-at 10 mg/ml. Cotransfectants of
NY-ESO-1 and HLA-A2 were used as a positive control.
Table 1. NY-ESO-1–derived Peptides with Binding Motifs 
to HLA-A2
No. Peptide sequence Position Specific lysis
1 SLAQDAPPLPV 108–118 0
2 SLLMWITQCFL 157–167 55
3 QLSISSCLQQL 146–156 1
4 QLQLSISSCL 144–153 1
5 LLMWITQCFL 158–167 15
6 RLTAADHRQL 136–145 5
7 FTVSGNILTI 126–135 1
8 ITQCFLPVFL 162–171 1
9 SLAQDAPPL 108–116 3
10 PLPVPGVLL 115–123 1
11 WITQCFLPV 161–169 5
12 SLLMWITQC 157–165 78
13 RLLEFYLAM 86–94 7
14 SISSCLQQL 148–156 6
15 LMWITQCFL 159–167 4
16 QLQLSISSC 144–152 1
17 CLQQLSLLM 152–160 1
18 QLSLLMWIT 155–163 84
19 NILTIRLTA 131–139 2
20 GVLLKEFTV 120–128 3
21 ILTIRLTAA 132–140 12
22 TVSGNILTI 127–135 4
23 GTGGSTGDA 7–15 9
24 ATPMEAELA 97–105 1
25 FTVSGNILT 126–134 1
26 LTAADHRQL 137–145 9
NY-ESO-1 peptides with binding motifs to HLA-A2, as analyzed by
computer calculation, and specific lysis of T2 cells pulsed with peptide
at 10 mg/ml (E/T 5 90:1) as assessed by a standard 51Cr–release assay.269 Jäger et al. Brief Definitive Report
evidence for the development of CTLs with specificity for
human melanoma cells (3, 17, 21–24). Using specific anti-
tumor CTLs as probes, a number of CTL targets have been
cloned on the basis of MHC class I–restricted recognition (1,
6). However, this approach involves cultured cancer cell
lines and stable CTL lines from the same patient, two re-
quirements that cannot easily be met with many tumor types.
With the demonstration that genes coding for CTL-recog-
nized tumor antigens elicit humoral immunity and can be
cloned by SEREX methodology, a technically less de-
manding approach defining immunogenic tumor antigens
is now available, one that extends the range of analysis to
tumor types that are not easily adaptable to in vitro growth
and are not sensitive targets for CTLs. A number of novel
tumor antigens have been defined by SEREX, including
two new members of the cancer–testis antigenic family, SSX2
(HOM-MEL-40) (5, 16), and NY-ESO-1 (15).
In this study, we identified a melanoma patient, NW38,
with high-titered antibody against NY-ESO-1. This pa-
tient had a large and highly necrotic tumor, and the sus-
tained release of intracellular antigens that are usually inac-
cessible to the immune system may account for the high
NY-ESO-1 titer. The establishment of an autologous cell
line that typed NY-ESO-1 positive provided target cells for
assessing CTL reactivity in this patient. A CTL line was es-
tablished from this patient that lysed the autologous mela-
noma cell line in an HLA-A2–restricted fashion. Using tar-
get cells transfected with NY-ESO-1 and HLA-A2, the
specificity of CTL reactivity was found to be coded by
NY-ESO-1. Computer analysis of the NY-ESO-1 se-
quence identified 26 peptides with HLA-A2–binding mo-
tifs. Screening of these peptides presented by T2 cells iden-
tified three sequences that were confirmed to be specifically
recognized by NW38-IVS-1. This is the first conclusive
demonstration of simultaneous antibody and CTL re-
sponses against a cancer–testis antigen in a single patient.
The strategy used in this study to generate and analyze
CTL reactivity to a SEREX-defined antigen can be used as
a model for investigating cellular immune responses to the
growing list of other SEREX antigens. Identification of
clones in SEREX requires high-titered IgG antibody, and
the development of such antibodies requires the help of
CD41 T cells. In this sense, SEREX can be thought of as a
method to define the CD41 T cell repertoire to human tu-
mor antigens. Also, the presence of both NY-ESO-1 anti-
body and CTLs in patient NW38 suggests that screening
for an antibody response may be a simple and effective way
to identify patients with concomitant CTL reactivity, and
this possibility is now being tested in other patients with
NY-ESO-1 antibody. In the absence of autologous tumor
cell lines, CD81 T cells can be stimulated with autologous
antigen-presenting cells that have been transfected with the
coding gene or fed purified protein antigens. A similar
strategy can be used to identify peptide targets for CD41
T cells.
A major objective in defining immunogenic human tu-
mor targets is to explore their use in the development of
cancer vaccines, and a number of clinical trials with various
vaccine constructs are currently underway. Although tu-
mor regression is the desired goal of a therapeutic vaccine,
this end point cannot be expected to be an effective way to
develop maximally immunogenic tumor vaccines. For this
purpose, reliable immunological assays are needed to mon-
itor the specificity and strength of specific immune reac-
tions generated by the vaccine. With the exception of vac-
cines aimed at inducing a humoral immune response such
as GM2 ganglioside vaccines, most vaccine trials are de-
signed to stimulate cellular immunity, particularly the de-
velopment of CTLs and CD41 T cells. These have been
difficult to detect in vaccine trials with MAGE peptides
(25), and difficult to interpret in trials with vaccines contain-
ing melanocyte differentiation antigens, since CTLs against
these antigens can be generated in vitro from nonvacci-
nated melanoma patients as well as normal individuals (26,
27). However, de novo induction and increase of preexist-
ing CTL reactivity have been detected after vaccination
with melanocyte differentiation antigens and observed to
be associated with cancer regressions in a limited number of
patients (13). The demonstration of a simultaneous anti-
body and CTL response to NY-ESO-1 in the same patient
suggests that serological methods may be useful in monitor-
ing vaccine trials with NY-ESO-1 and other tumor anti-
gens eliciting a humoral immune response.
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